Regeneron Alnylam collaborate on a $1bn eye & CNS R&D agreement
Category: #health  By Pankaj Singh  Date: 2019-04-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Regeneron  Alnylam collaborate on a $1bn eye & CNS R&D agreement

Regeneron Pharmaceuticals Inc. and Alnylam Pharmaceuticals Inc. have reportedly entered into a definitive collaborative deal. Authentic sources claim that the deal has been inked in a major effort to discover, advance and commercialize treatments for the CNS (central nervous system) and the eye.

As per the terms of the transaction, Regeneron is making an upfront payment of $400 million to Alnylam and further acquiring additional $400 million in equity at $90 per share. Alnylam is to receive another $200 million as milestone payment during the early development stage for the CNS & the eye programs.  

As reported by Regeneron, Alnylam looks to work exclusively with Regeneron and discover RNAi therapeutics for the two fundamental indications comprising the eye & the CNS diseases. Regeneron will lead the development & marketing of the programs, while Alnylam will be accountable for the milestone payments and royalties.

George D. Yancopoulos, President & Chief Scientific Officer, Regeneron, said that the company’s believes its resources can be best used by investing in potentially game-changing science, which is certain to yield effective medicines for patients suffering from serious diseases. He further commented that the latest collaboration incorporates the emerging, promising RNAi technology with the world-leading genetics & target discovery engine of Regeneron.  

John Maraganore, the Alnylam CEO, said that the latest industry-leading association is being observed as an important prospect for RNAi therapeutics, which are potentially transformative medicines for the CNS as well as ocular diseases.

Regeneron and Alnylam are planning to advance the programs up to 30 targets, and several of these will be turned into clinical development in the course of the initial 5-year discovery period, which also involves an option for partnership extension.

Besides this deal, Regeneron is leading a consortium for the DNA sequencing of about 500,000 UK residents, which will be merging the company’s genetic research expertise with the RNAi technology of Alnylam.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Dressbarn confirms 53 stores to close in August as wind down nears
Dressbarn confirms 53 stores to close in August as wind down nears
By Pankaj Singh

Ascena shares have been down by more than 75% this year and are trading at below $1 Ascena Retail Group, an American retailer for women’s clothing, recently announced that it is going to shut down 53 locations of Dressbarn by the end of August...

Japan introduces working group to examine impact of Facebook’s Libra
Japan introduces working group to examine impact of Facebook’s Libra
By Pankaj Singh

Japan is looking to garner greater support due to the wide range of policies which can be affected by digital currencies. Japanese authorities have reportedly established a working group to discuss the impact Libra digital coin proposed by Facebook ...

Ligand Pharma announces positive results from trial of CE-Iohexol
Ligand Pharma announces positive results from trial of CE-Iohexol
By Pankaj Singh

Ligand Pharmaceuticals, a US-based biopharmaceutical company recently announced positive top line results from clinical trial of its internal CE (Captisol-enabled) Iohexol program. The study attained primary endpoint indicating pharmacokinetic b...